Impact Therapeutics names CEACAM5 dual-payload ADC IMP3201 as preclinical candidate

• Impact Therapeutics nominated IMP3201 as a preclinical candidate, a CEACAM5-targeted dual-payload antibody-drug conjugate from its proprietary platform.
• No clinical-study results were reported or scheduled for presentation; the update focused on preclinical work and development plans.
• Preclinical findings showed stronger anti-tumor activity with a favorable therapeutic window versus conventional TOPO inhibitor-based ADC approaches.
• The program targets gastrointestinal cancers, aiming to address resistance seen with single-payload TOPO inhibitor ADCs.
• The nomination marks the company’s first preclinical candidate from its dual-payload ADC platform, supporting expansion of its next-generation ADC pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12256655), on July 26, 2026, and is solely responsible for the information contained therein.